Project Grant R43AI197772
Award Date 8/17/26
Completion Date 7/31/27
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $306,810 to Capture Bioscience Inc. on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of a high-throughput autoimmune antibody detection platform. Capture Bioscience will adapt its Beads by Time-of-Flight (B-TOF) technology to create a comprehensive autoimmunity panel capable of simultaneously...
- The National Institute of Allergy and Infectious Diseases awarded Impact Proteomics LLC $320,863 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish clinical and technical feasibility of an immunoproteomics diagnostic platform for autoimmune disease detection and monitoring. Impact Proteomics will develop and validate an IP-to-mass spectrometry (IP-to-MS) workflow that leverages a patented PromTag system to separate autoantigens from...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $127,926 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize autoreactive B cells and their roles in systemic lupus erythematosus (SLE) pathogenesis using immune organoids. The research investigates how autoreactive B cells transition from a...
- The National Institute of Allergy and Infectious Diseases awarded Applied Biomedical Science Institute $976,318 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the molecular mechanisms underlying ultralong complementarity-determining region H3 (CDR H3) antibodies produced by cattle. The project investigates two major objectives. The first examines the atypical V(D)J recombination event that generates ultralong CDR H3 genes, specifically the...
- The National Institute of Allergy and Infectious Diseases awarded Celdara Medical, LLC $320,863 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop precision chimeric antigen receptor (CAR) natural killer cell therapy targeting VK4-1-overexpressing autoreactive B cells in systemic lupus erythematosus. The Phase I SBIR project seeks to selectively remove disease-causing B cells while preserving non-pathogenic immune function, using humanized...
- The National Institute of Allergy and Infectious Diseases awarded La Jolla Institute for Immunology $929,095 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize immune cell populations in lymphoid tissue from systemic lupus erythematosus patients and healthy controls using minimally invasive nasal swab sampling combined with flow cytometry and transcriptomic profiling. The research addresses gaps in understanding tissue-specific immune...
- The National Institute of Allergy and Infectious Diseases awarded The Feinstein Institutes for Medical Research $209,375 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of autophagy in B cell tolerance and its relationship to systemic lupus erythematosus. The research examines how autophagy defects contribute to loss of B cell tolerance in autoimmune disease, specifically exploring crosstalk between autophagy pathways and...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $855,342 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the pathogenic roles of follicular helper T (TFH) cells in systemic lupus erythematosus. The research seeks to understand how SLE disease settings reprogram TFH cell differentiation and function to promote autoimmune disease pathology. The recipient will assess how the IGF1R/IGFBP4...
- The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization. Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The...
- The National Institute of Allergy and Infectious Diseases awarded $499,175 to the University of Pittsburgh on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct genetic and functional dissection of tissue-infiltrating and age-associated B cells in murine lupus models. The research aims to identify and characterize pathogenic B cell subsets in systemic lupus erythematosus (SLE), with particular focus on age-associated B cells (ABCs) that...